

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Adzynma (ADAMTS13 recombinant-krhn)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name: Specialty: * DEA, NPI or TIN:		*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*					
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID:	* Date of Birth:	* Date of Birth:		
Office Fax:			* Patient Street Address:				
Office Street Address:		City:	State:	Zip:			
City:	State:	Zip:	Patient Phone:		_		
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication Requested: Adzynma 1500 unit kit Adzynma 500 unit kit Adzynma 1500 unit vial Adzynma 500 unit vial							
Dose:	Freque	ncy of therapy:	Г	ouration of therapy	y:		
J-Code:	ICD10:						
What is your patient's current weight? lb/kg							
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Where will this medication be obtained? ☐ Accredo Specialty Pharmacy** ☐ Prescriber's office stock (billing on a medical claim form) ☐ Other (please specify):			☐ Retail pharmacy ☐ Home Health / Home Infusion vendor **Cigna's nationally preferred specialty pharmacy				
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557							
Clinical Information:							
**This drug requires support for all answers must be at			ting, chart notes, lab/test	results, etc). Sup	oportive documentation		
Does your patient have a dia	agnosis of cong	enital thrombotic thro	ombocytopenic purpura?		Yes ☐ No ☐		
(if no) Please provide the patient's diagnosis or reason for treatment.							
Does your patient have a ba refers to before any treatme					IU/dL)? Note: Baseline Yes		
Does your patient have anti-ADAMTS13 autoantibodies as determined by a diagnostic test?					Yes ☐ No ☐		
Does your patient have a pa	ıthogenic varian	t or a mutation in the	ADAMTS13 gene? Note: F	athogenic variani	ts or gene mutations are		

usually homozygous or compound heterozygous.	Yes 🗌 No 🗌
Is the medication prescribed by or in consultation with a hematologist?	Yes 🗌 No 🗌
What is the intended purpose of the medication? Routine prophylaxis On demand therapy Both routine prophylaxis and on demand therapy	
(If routine prophylaxis) Is the requested dosing up to 40 IU/kg administered by intravenous infusion once weekly?	Yes ☐ No ☐
(If on demand therapy) Is the requested dosing up to 135 IU/kg administered by intravenous infusion per week as ne treatment of acute event(s)? Note: On demand therapy is given as a daily dose until 2 days after the acute event results total weekly dose should not exceed 135 IU/kg.	
(If both routine prophylaxis and on demand therapy) Is the requested dosing for routine prophylaxis up to 40 IU/kg ac intravenous infusion once weekly?	dministered by Yes
(If both routine prophylaxis and on demand therapy) Is the requested dosing for on demand therapy up to 135 IU/kg intravenous infusion per week as needed for the treatment of acute event(s)? Note: On demand therapy is given as a 2 days after the acute event resolves; however, the total weekly dose should not exceed 135 IU/kg.	
Is this a new start or continuation of therapy with the requested medication? If patient has been taking samples, plea start." New start Continuation of therapy	se pick "new
Additional pertinent information (Please provide any additional pertinent clinical information, including: if the patient the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).	nt is currently on
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the insurer its designees may perform a routine audit and request the medical information necessary to verify the according information reported on this form.	
Prescriber Signature: Date:	
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScri	ipts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigns	

v050124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005